Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?
Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?
复制标题
DOI：
10.3390/biomedicines4030013
复制
发表时间：
2016-07-07
期刊：
影响因子：
4.7
通讯作者：
Cripe TP
中科院分区：
文献类型：
--
作者：
Denton NL;Chen CY;Scott TR;Cripe TP
由于化疗和放射治疗的毒性限制，癌症治疗仍然是一个挑战。选择性复制和摧毁癌细胞的溶瘤病毒越来越受到人们的关注。除了直接细胞裂解外，这些载体还能刺激抗肿瘤免疫反应。肿瘤免疫的一个关键调节因素是肿瘤相关巨噬细胞群。巨噬细胞可以通过促炎刺激抗肿瘤反应来支持溶瘤病毒治疗，但代价是阻碍直接溶瘤反应，或者通过免疫抑制保护病毒复制，代价是阻碍抗肿瘤免疫反应。尽管成人和儿童肿瘤之间巨噬细胞的相互作用相似，而且有大量研究支持巨噬细胞在成人肿瘤中的调节作用，但很少有研究研究巨噬细胞调节在儿童癌症中的作用或免疫治疗的调节。我们回顾了关于巨噬细胞在癌症中的知识现状及其对溶瘤病毒治疗的影响。
Cancer therapy remains a challenge due to toxicity limitations of chemotherapy and radiation therapy. Oncolytic viruses that selectively replicate and destroy cancer cells are of increasing interest. In addition to direct cell lysis, these vectors stimulate an anti-tumor immune response. A key regulator of tumor immunity is the tumor-associated macrophage population. Macrophages can either support oncolytic virus therapy through pro-inflammatory stimulation of the anti-tumor response at the cost of hindering direct oncolysis or through immunosuppressive protection of virus replication at the cost of hindering the anti-tumor immune response. Despite similarities in macrophage interaction between adult and pediatric tumors and the abundance of research supporting macrophage modulation in adult tumors, there are few studies investigating macrophage modulation in pediatric cancers or modulation of immunotherapy. We review the current state of knowledge regarding macrophages in cancers and their influence on oncolytic virotherapy.